DGAP-Adhoc: biolitec AG revenue increases to Euro 28.05 million in the first nine months 07/08 - EBIT amounts to Euro 3.2 million

biolitec AG / Quarter Results

30.05.2008 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Jena, May 30, 2008 – biolitec AG, Jena, listed in the Prime Standard of the
Frankfurt stock exchange (ISIN DE0005213409) increased consolidated
revenues by 6% to Euro 28.05 million during the first nine months ending
March 31, 2008 (previous year: Euro 26.4 million). The gross profit
amounted to Euro 19.4 million (last fiscal year: Euro 18.3 million) and
EBIT amounted to Euro 3.2 million.

Net income amounted to Euro 2.3 million (previous year: Euro 3.2 million)
due to the significant investment in marketing and sales for the in office
BPH treatment 'LIFE™' and the improved vein treatment procedure 'ELVeS™
PainLess'.

Third quarter revenues were lower (Euro 8.9 million compared to Euro 9.4
million) than in the previous year, due to the unfavourable investment
climate in the USA, its impact on the investment cycle and the unfavourable
dollar exchange rate. The company expects this negative effect to continue
in the coming months and expects fiscal year sales and profit to fall short
of last year’s level.

Laser sales for the first nine months grew by 10% due to the demand for the
company’s BPH Evolve laser. Nine months fiber optic (disposables) sales
increased by 3% in total. biolitec’s major revenues were again generated in
Europe and North America. With Euro 13.1 million, sales in North America
exceeded previous year’s nine months sales by 6 %, accounting for 47% of
total sales. European sales amounted to Euro 12.8 million (March 31, 2007:
Euro 12.6 million).
With Euro 4.7 million (17% of sales) in the first nine months of the
business year, R&D expenditures remain at a high level, ensuring the
group’s long term growth and profitability.
biolitec AG expects dynamic sales growth to resume in the coming fiscal
year.
DGAP 30.05.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       biolitec AG
              Winzerlaer Straße 2a
              07745 Jena
              Deutschland
Phone:        +49 (0)3641 5 08-5 50
Fax:          +49 (0)3641 5 08-5 99
E-mail:       info@biolitec.de
Internet:     www.biolitec.de
ISIN:         DE0005213409
WKN:          521340
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Stuttgart, München, Hamburg, Düsseldorf
End of News                                     DGAP News-Service
---------------------------------------------------------------------------